DDInter1544 DDInter731
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Fesoterodine {u} (Compound) resembles {v} (Compound) Tolterodine
Fesoterodine {u} (Compound) binds {v} (Gene) CYP2D6
Fesoterodine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Fesoterodine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brompheniramine
Fesoterodine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lumacaftor
Fesoterodine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Fesoterodine {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Fesoterodine (Compound) resembles Tolterodine (Compound)
Fesoterodine (Compound) binds CYP2D6 (Gene)
Fesoterodine (Compound) causes Hypersensitivity (Side Effect)
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Fesoterodine may lead to a major life threatening interaction when taken with Idelalisib
Fesoterodine may lead to a major life threatening interaction when taken with Clarithromycin